Key Takeaways
Ligand Pharmaceuticals (LGND) is making a bold move to solidify its position as a leading biopharma royalty aggregator, announcing a definitive agreement to acquire XOMA Royalty Corporation (XOMA) for approximately $739 million in cash. This transaction, valued at $39.00 per share, represents a notable 14% premium to XOMA Royalty’s 30-trading day volume-weighted average price as of April 24, 2026. Beyond the cash, XOMA shareholders will also receive a non-transferable Contingent Value Right (CVR) per share, entitling them to 75% of the net proceeds from certain pending litigation at XOMA.
The market has reacted positively to the news, with XOMA shares trading up 9.37% to $41.45 as of April 27, 2026, 10:37 EDT. This price, above the $39.00 cash offer, clearly indicates that investors are assigning tangible value to the CVR, which offers a potential "free" upside beyond the immediate cash payout. For Ligand, this acquisition is a strategic play to further accelerate profit growth and strengthen its already robust royalty portfolio, creating a combined entity with unparalleled scale and diversification in the biopharma royalty space.
Both Ligand and XOMA operate on a similar model: acquiring future economic rights, such as royalties and milestones, associated with therapeutic candidates licensed to larger pharmaceutical or biotechnology companies. This provides non-dilutive funding to drug developers while offering investors exposure to the biotech industry's upside with reduced R&D risk. The merger of these two players is set to create a true powerhouse, combining their extensive and complementary portfolios into a single, more formidable platform.
The deal has received unanimous approval from both Ligand and XOMA Royalty Boards of Directors, with key XOMA shareholders, including BVF Partners (owning approximately 21% of outstanding shares, or 44% assuming preferred stock conversion), agreeing to support the transaction. Expected to close in the third quarter of 2026, subject to customary conditions and regulatory approvals, this merger is poised to reshape the biopharma royalty aggregation landscape, promising enhanced value for Ligand shareholders and a lucrative exit for XOMA investors.
The strategic rationale behind Ligand’s acquisition of XOMA Royalty is clear: to create an undisputed leader in the biopharma royalty aggregation sector. Ligand already boasts a diversified portfolio with economic interests in over 100 development and commercial-stage assets, complemented by its proprietary Captisol® and NITRICIL™ technologies. XOMA, on the other hand, has been a highly active player, systematically acquiring distressed companies and their royalty streams, building a portfolio of over 120 assets. This includes blockbuster royalties on promising drugs like Ojemda (projected $231 million in 2026 sales) and Miplyffa (projected $130 million in 2026 sales).
The combined entity will manage a portfolio of over 200 assets, including seven new commercial products, significantly expanding its reach across various therapeutic areas and development stages. This scale brings substantial benefits, primarily through enhanced diversification. A broader portfolio mitigates the inherent risks associated with individual drug development programs, smoothing out revenue streams and reducing volatility. If one asset faces clinical setbacks or market challenges, the impact on the overall portfolio is lessened.
Furthermore, the merger is expected to generate significant operational synergies. A larger, more diversified platform can attract a wider array of deal opportunities, from early-stage financing to late-stage royalty acquisitions. This increased deal flow, combined with a stronger balance sheet and greater negotiating leverage, positions the combined company to secure more favorable terms on future investments. Ligand’s stated $1 billion in deployable capital, highlighted at its 2025 Investor Day, will be instrumental in driving this long-term royalty revenue growth through disciplined allocation, now supercharged by XOMA's pipeline.
XOMA’s expertise in acquiring negative enterprise value companies and contingent value rights, often funded with limited cash, complements Ligand’s strategy of funding high-value programs. This blend of aggressive portfolio expansion and strategic technology licensing creates a robust, multi-faceted business model. The combined entity will be better equipped to capitalize on the growing trend of biotech companies seeking non-dilutive capital and de-risking their balance sheets through asset sales, ensuring a steady pipeline of potential deals for years to come.
The acquisition of XOMA Royalty is set to significantly enhance Ligand's financial profile, with management already updating its 2026 guidance to reflect the expected accretion. Ligand now projects total revenue for 2026 to be between $270 million and $310 million, a notable increase from its prior guidance of $245 million to $285 million. More specifically, royalty revenue, the core of their business, is now expected to reach $225 million to $250 million, up from the previous range of $200 million to $225 million. This represents a substantial boost, underscoring the immediate impact of XOMA's revenue-generating assets.
The deal is also anticipated to be immediately accretive to Ligand's earnings. The company has raised its core adjusted earnings per diluted share guidance for 2026 to $8.50 to $9.50, an improvement over the prior $8.00 to $9.00 range. Looking further ahead, Ligand expects the acquisition to be accretive by an impressive $1.50 per share to adjusted EPS in 2027, signaling strong long-term value creation. This accretion is driven by XOMA's highly profitable business model, evidenced by its trailing twelve months (TTM) financials, which show a robust gross margin of 94.3% and a net margin of 56.4%.
XOMA's recent financial performance highlights the quality of the assets Ligand is acquiring. In fiscal year 2025, XOMA reported an 83.1% year-over-year revenue growth and a staggering 329.4% increase in net income, with EPS growing by 188.5%. These figures demonstrate XOMA’s ability to generate substantial cash flows from its diversified portfolio. While the acquisition is an all-cash deal, Ligand has ample financial flexibility, including its $1 billion in deployable capital, to fund the transaction through existing cash and credit facilities without undue strain on its balance sheet.
This strategic move aligns perfectly with Ligand's long-term vision. The company had previously projected a compound annual growth rate (CAGR) of at least 23% for royalty receipts over the next five years, driven by key assets like Filspari, Ohtuvayre, Capvaxive, Qarziba, and Zelsuvmi. The integration of XOMA's portfolio, including its own blockbuster royalties and late-stage pipeline assets, is expected to further bolster and potentially exceed this ambitious growth trajectory, solidifying Ligand's position as a consistent and predictable revenue generator in the biopharma sector.
For XOMA Royalty shareholders, the acquisition by Ligand represents a clear and attractive value realization event. The offer of $39.00 per share in cash provides immediate liquidity and a significant premium of approximately 14% over the 30-day volume-weighted average price prior to the announcement. This cash component alone offers a strong return, especially for investors who have been with XOMA through its recent period of aggressive growth and portfolio expansion.
However, the deal's structure includes a crucial element that provides additional, de-risked upside: the Contingent Value Right (CVR). This CVR entitles XOMA stockholders to 75% of the net proceeds from specific pending litigation related to Janssen. While the outcome and timing of litigation are inherently uncertain, this CVR offers a potential bonus that could significantly enhance the total return for XOMA shareholders without requiring them to bear the direct costs or risks of the legal process. The fact that XOMA's stock price jumped above the $39.00 cash offer to $41.45 on the news indicates the market is already pricing in a meaningful value for this CVR.
XOMA has been on an impressive growth trajectory, systematically acquiring royalty streams from distressed biotechs. In 2025 alone, the company completed seven acquisitions and 11 notable transactions, including LAVA Therapeutics and Turnstone Biologics. This strategy led to over $50 million in annual receipts and a 68% surge in royalty revenue in 2025. The company's TTM EPS of $1.63 and a P/E ratio of 25.50 (as of April 27, 2026) reflect a healthy, growing business.
Despite this strong performance, analyst consensus price targets for XOMA had ranged widely, with some as high as $97.00 and others at $50.00, averaging around $65.75. While the $39.00 cash price is below these higher targets, the combination of immediate cash and the CVR provides a more certain and accelerated path to value compared to waiting for the full realization of XOMA's long-term pipeline potential, which always carries clinical and regulatory risks. This deal allows XOMA shareholders to lock in substantial gains while still participating in a specific, high-potential future event.
While the Ligand-XOMA merger presents a compelling growth story, investors should be mindful of potential risks. Integration risk is always a factor in M&A; combining two extensive royalty portfolios and their underlying agreements requires careful management to ensure a smooth transition and realize projected synergies. Any delays in regulatory approvals or closing conditions could also introduce uncertainty, though the transaction is expected to close in Q3 2026 with strong shareholder support.
For Ligand, the success of this acquisition hinges on the continued performance of the combined portfolio's underlying assets. While diversification mitigates risk, a significant setback for a major royalty-generating drug, such as unexpected competition, slower-than-anticipated market adoption, or adverse clinical trial results for late-stage assets, could impact revenue projections. The royalty model relies on the success of third-party partners, meaning Ligand's revenue is indirectly exposed to their operational and clinical execution.
However, the opportunities significantly outweigh these risks. The expanded portfolio of over 200 assets, including seven new commercial products, provides a broader base for consistent revenue generation. Ligand's enhanced scale and financial strength will likely lead to even more attractive deal flow, allowing it to acquire high-value royalty interests and further diversify its income streams. The company's proven track record of using acquisitions to expand its royalty base, as seen with APEIRON Biologics and Pelthos, suggests a disciplined approach to M&A.
The CVR for XOMA shareholders is a unique opportunity, offering a direct stake in the outcome of the Janssen litigation without the direct exposure to legal costs. If the litigation yields a favorable result, this could provide a substantial additional payout. For Ligand, the acquisition of XOMA's expertise in identifying and acquiring distressed assets and contingent value rights could prove invaluable, enhancing its own deal-making capabilities and potentially uncovering new avenues for growth within the dynamic biopharma landscape.
The combination of Ligand and XOMA creates a formidable entity poised for sustained growth in the biopharma royalty space. Ligand's updated 2026 guidance, reflecting higher revenue and EPS expectations, underscores the immediate financial benefits of this strategic move. The projected $1.50 EPS accretion in 2027 further solidifies the long-term value proposition for Ligand shareholders.
For XOMA investors, the deal offers a compelling exit with immediate cash and a valuable CVR, providing a de-risked path to realizing the value of their investment. The market's positive reaction, with XOMA shares trading above the cash offer, confirms the perceived value of the litigation upside. This merger is a testament to the growing importance of royalty aggregators in financing biotech innovation and provides a robust platform for future expansion.
The combined company's diversified portfolio, enhanced deal-making capabilities, and strong financial position create a resilient business model. Investors looking for exposure to the biotech sector with reduced direct R&D risk will find the new Ligand an even more attractive proposition. This is a strategic consolidation that positions the combined entity for continued leadership and significant shareholder value creation in the years to come.
Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.
